Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

25.48 +0.19 (+0.75%)
Official Closing Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
2 S&P 500 Stocks with Competitive Advantages and 1 We Avoid
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural... 
Via StockStory
Topics Stocks
News headline image
1 Healthcare Stock to Target This Week and 2 We Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 17.2% over... 
Via StockStory
Topics Stocks
News headline image
U.S. Scales Back The Number Of Vaccines It Recommends For Every Child ↗
Move comes in response to a presidential memorandum issued by President Donald Trump in December, aimed at aligning U.S. vaccination practices with other developed nations. 
Via Stocktwits
Topics Government
News headline image
Flu Season's Here—This Dividend-Payer Controls the Shot Market ↗
Via MarketBeat
Topics Artificial Intelligence Death
Looking for the most active stocks in the S&P500 index on Monday? ↗
Via Chartmill
News headline image
This Flying-Under-the-Radar Pharma Stock Pays Nearly 7% (While Everyone's Sleeping) ↗
Investors seem to be underestimating this company's foreseeable future. 
Via The Motley Fool
News headline image
These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever ↗
Via MarketBeat
News headline image
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
News headline image
Is It Time to Dump Your Shares of Eli Lilly? ↗
Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game. 
Via The Motley Fool
News headline image
Better Dividend Stock: Ford vs. Pfizer ↗
Both Ford and Pfizer have very attractive dividend yields. 
Via The Motley Fool
Topics Economy Electric Vehicles Government
News headline image
26 Top Dividend Stocks to Buy and Hold in 2026 ↗
Another year, another long list of great dividend stocks. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Stocks Under $50 with Questionable Fundamentals
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
News headline image
How Safe Is Pfizer's Dividend As 2026 Begins? ↗
Income investors probably don't need to worry about a dividend cut from Pfizer in the new year. 
Via The Motley Fool
News headline image
2 Predictions for Pfizer in 2026 ↗
The company's prospects are stronger than its stock-market performance in 2025 suggests. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Momentum in Healthcare and Banking to Persist in 2026 as AstraZeneca and Citigroup Lead the Charge
As the global markets open for the first week of 2026, a clear narrative has emerged: the "recovery plays" of 2025 have officially transformed into the "expansion leaders" of the new year. Following a... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls
Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s... 
Via MarketMinute
Topics Economy Intellectual Property World Trade
News headline image
The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500
As the calendar turns to 2026, Alnylam Pharmaceuticals (Nasdaq: ALNY) stands at the threshold of a new era. Once a speculative pioneer in the arcane world of RNA interference (RNAi), the... 
Via PredictStreet
Topics Economy Intellectual Property Stocks
News headline image
The Great Rebound: US M&A Poised for Record-Breaking 2026 as Interest Rates Stabilize
As the calendar turns to January 1, 2026, the United States financial markets are witnessing a dramatic transformation in the landscape of corporate dealmaking. After a multi-year "deal desert"... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30
As the calendar turns to January 1, 2026, Pfizer Inc. (NYSE: PFE) finds itself in a position that would have been unthinkable during the height of the pandemic. Once the darling of the pharmaceutical... 
Via MarketMinute
Topics Intellectual Property
News headline image
Economic Revolution or Looming Recession? Trump’s ‘A++’ Claims Clash with Wall Street’s Cautious 2026 Outlook
As the sun rises on January 1, 2026, the United States finds itself at a historical crossroads, caught between the triumphant rhetoric of an "Economic Revolution" and the sobering data of a cooling... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
Should You Buy Pfizer While It's Under $30? ↗
It might not pay off immediately, but it could, eventually. 
Via The Motley Fool
Topics Government Intellectual Property World Trade
News headline image
Investing $122,100 in These 3 High-Yield Dividend Stocks Could Make You $10,000 in Reliable Passive Income in 2026 ↗
The money could flow in with these great dividend stocks. 
Via The Motley Fool
News headline image
1 Momentum Stock to Target This Week and 2 That Underwhelm
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant... 
Via StockStory
News headline image
Where Will Pfizer Be in 5 Years? ↗
Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the big leagues. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings
As 2025 draws to a close, the pharmaceutical industry stands at a historic crossroads. The year was defined by a widening chasm between the "metabolic haves"—those profiting from the global obesity... 
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake ↗
Via MarketBeat
News headline image
2 Unstoppable Dividend Stocks to Double Up on Right Now ↗
It's always a great time to buy quality dividend stocks. 
Via The Motley Fool
News headline image
Pfizer Leads New Wave Of 2026 US Drug Price Hikes Despite Trump’s Drug Cost Crackdown: Report ↗
Drugmakers are outlining 2026 list price changes, with most adjustments typically announced in January. 
Via Stocktwits
Topics Economy Government
News headline image
Tuesday's session: most active stock in the S&P500 index ↗
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Tuesday and uncover the stocks that are leading the way in terms of trading volume and market... 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.